June 26 (Reuters) - Voyager Therapeutics Inc
* Voyager Therapeutics announces clinical trial update with VY-AADC01 for advanced Parkinson’s disease
* Voyager Therapeutics Inc - Administration of VY-AADC01 with this posterior approach was well-tolerated by patient
* Voyager Therapeutics Inc - No serious adverse events were reported and patient was discharged from hospital day after surgery Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.